ArticleScientific reports2024
Myostatin as a plausible biomarker for early stage of sarcopenic obesity.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Endocrinological aspects of sarcopenic obesity.Annals of medicine · 2026Review
- Article
- From Continuous-Flow Mechanical Circulatory Support to Heart Transplantation: Hemodynamic, Immunometabolic, and Body Composition Determinants of Rehabilitation Outcomes.Journal of clinical medicine · 2026Review
- Sarcopenia Definitions and Diagnostic Challenges Across Diverse Clinical Populations: A Scoping Review.Health science reports · 2026Article
- Myostatin in Obesity: A Molecular Link Between Metabolic Dysfunction and Musculotendinous Remodeling.International journal of molecular sciences · 2026Review
- Beyond body mass index: phenotypic and circulating biomarkers for the identification and characterization of sarcopenic obesity.Frontiers in nutrition · 2026Review
- Inflammation-Insulin Resistance Crosstalk and the Central Role of Myokines.International journal of molecular sciences · 2025Review
- Prevalence and association of sarcopenic obesity with locomotive syndrome based on the 2024 Consensus Statement of the Japanese Working Group on Sarcopenic Obesity in community-dwelling Japanese women.Journal of physical therapy science · 2025Article
- Can Myokines Serve as Supporters of Muscle-Brain Connectivity in Obesity and Type 2 Diabetes? Potential of Exercise and Nutrition Interventions.Nutrients · 2025Review
- Myokine Levels in Relation to Bone Markers and Adipokines in Children with Prader-Willi Syndrome During Growth Hormone Therapy and Dietary Intervention.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Since sarcopenic obesity (SO) impacts negatively on our health, early detection of SO is essential. However, prevalence of SO in an apparently healthy population has not been well examined. This study aimed to elucidate the prevalence and related factors of SO in middle-aged women, and to investigate useful diagnostic criteria for SO. Body component analyses were conducted on 432 female Osaka University employees aged 30-59 during their health checkups. Healthy (H) and SO groups were defined using cutoff values of 5.7 kg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.